Precision BioSciences, Inc. DTIL
9.15 USD -0.35 (-3.68%)
At closeNov 12, 2026, 7:37 AM EST
9.00 -0.15 -1.64%
Pre-market · Nov 12, 7:37 AM ET
8.93 Day range 9.59
3.53 52-week range 11.29
- YTD
- +119.95%
- 1 year
- +52.50%
News
seekingalpha.com Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript Precision BioSciences, Inc. ( DTIL ) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B November 9, 2026 8:00 AM EST Company Participants Naresh Tanna - Chief Financial Officer…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
businesswire.com Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
businesswire.com Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
benzinga.com UPDATE: Precision BioSciences Q3 Adj. EPS $(0.74) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.85) by 12.94 percent. This is a 59.78 percent increase over losses…
benzinga.com Precision BioSciences Q3 EPS $(0.28) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.85) by 67.06 percent. This is a 84.78 percent increase over losses…- benzinga.com iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.2 million. Biodexa…- benzinga.com Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve function. This novel approach, aiming to restore near full-length dystrophin, is applicable for up to…
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.- benzinga.com Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026 – Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy –Precision BioSciences, Inc. (NASDAQ:DTIL), a…
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
benzinga.com Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026 Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD…- benzinga.com Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20 Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Outperform rating and announces Price Target of $20.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
benzinga.com Why Is Precision BioSciences Stock Gaining Wednesday? Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.- benzinga.com Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study - New biopsy data demonstrate thatPBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -- In the <1% of cccDNA…
benzinga.com Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
benzinga.com Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting – New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to…- benzinga.com Precision BioSciences Q1 EPS $(0.75) Misses $(0.66) Estimate, Sales $10.838M Beat $4.050M Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 15.38 percent. This is a 66.06 percent increase over…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
benzinga.com iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15 iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.The poster presentation at SIMD will feature one-year post-treatment…- benzinga.com Jones Trading Assumes Precision BioSciences at Buy, Announces Price Target of $30 Jones Trading analyst Catherine Novack assumes Precision BioSciences (NASDAQ:DTIL) with a Buy rating and announces Price Target of $30.
- benzinga.com Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV - France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company…
- benzinga.com Earnings Scheduled For March 12, 2026
- benzinga.com Precision BioSciences Receives Two Notices Of Allowance From USPTO For Patent Applications Relating To PBGENE-HBV Program Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
- benzinga.com Precision BioSciences Says FDA Grants Fast Track Designation To PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy – Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy –– March 17, 2026 virtual webinar…
- benzinga.com Precision BioSciences Lands $7.5M Milestone Payment From TG Therapeutics In MS Drug Trial Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
- benzinga.com Precision BioSciences Receives Study May Proceed Notification From FDA, Allowing Co To Initiate IRB Activities And Clinical Trial Site Activation For FUNCTION-DMD Phase 1/2 Clinical Trial For PBGENE-DMD – U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) ––…
benzinga.com Earnings Scheduled For November 3, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Earnings Scheduled For May 15, 2025
- benzinga.com Earnings Scheduled For March 26, 2025
benzinga.com Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 4, 2023 Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For May 9, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's morning session saw 84 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For March 9, 2023 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 325 companies set new 52-week lows.